Among them, p53 protein, primarily known as a tumor suppressor, has been proposed as a new player in NAFLD pathogenesis, and growing evidences highlight its relevance as metabolic modulator (Panasiuk et al. 2006; Derdak et al. 2013). This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.